Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | RHOC | P08134 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503815 | 0.84 | HPGD (0.70) | TSHRCYP2C19HPGDALOX15MEN1 | |
| SCHEMBL1265003 | 0.84 | HIF1A (0.63) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL15219384 | 0.84 | HIF1A (0.52) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL12959478 | 0.84 | HIF1A (0.52) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL430127 | 0.84 | HIF1A (0.52) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL428206 | 0.83 | HIF1A (0.49) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL12959479 | 0.81 | HIF1A (0.49) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL30080693 | 0.80 | L3MBTL1 (0.75) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL4935101 | 0.80 | L3MBTL1 (0.75) | HIF1ACYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL13503960 | 0.79 | POLB (0.74) | HIF1ATSHREPHX2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | HIF1A 147/4885CYP3A4 237/4885USP2 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.